These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30058109)

  • 1. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
    Lv C; Liu X; Zheng Q; Chen H; Yang X; Zhong J; Wang Y; Duan J; Wang Z; Bai H; Wu M; Zhao J; Wang J; Wang Z; An T; Zhuo M
    Thorac Cancer; 2018 Sep; 9(9):1166-1173. PubMed ID: 30058109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
    Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
    Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
    Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
    Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
    Ardizzoni A; Tiseo M; Boni L
    Eur J Cancer; 2014 Sep; 50(13):2211-8. PubMed ID: 24981975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
    Lycan TW; Pardee TS; Petty WJ; Bonomi M; Alistar A; Lamar ZS; Isom S; Chan MD; Miller AA; Ruiz J
    PLoS One; 2016; 11(10):e0164244. PubMed ID: 27732654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
    Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
    Enomoto Y; Inui N; Imokawa S; Karayama M; Hasegawa H; Ozawa Y; Matsui T; Yokomura K; Suda T
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):499-505. PubMed ID: 26134440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
    Spigel DR; Dowlati A; Chen Y; Navarro A; Yang JC; Stojanovic G; Jove M; Rich P; Andric ZG; Wu YL; Rudin CM; Chen H; Zhang L; Yeung S; Benzaghou F; Paz-Ares L; Bunn PA;
    J Clin Oncol; 2024 Jul; 42(19):2317-2326. PubMed ID: 38648575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.
    Tiseo M; Buti S; Boni L; Mattioni R; Ardizzoni A
    Lung Cancer; 2014 Oct; 86(1):91-5. PubMed ID: 25130081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.
    Apostolidis L; Bergmann F; Jäger D; Winkler EC
    Cancer Med; 2016 Sep; 5(9):2261-7. PubMed ID: 27456539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
    Gray JE; Heist RS; Starodub AN; Camidge DR; Kio EA; Masters GA; Purcell WT; Guarino MJ; Misleh J; Schneider CJ; Schneider BJ; Ocean A; Johnson T; Gandhi L; Kalinsky K; Scheff R; Messersmith WA; Govindan SV; Maliakal PP; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2017 Oct; 23(19):5711-5719. PubMed ID: 28679770
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
    Evans TL; Cho BC; Udud K; Fischer JR; Shepherd FA; Martinez P; Ramlau R; Syrigos KN; Shen L; Chadjaa M; Wolf M
    J Thorac Oncol; 2015 Aug; 10(8):1221-8. PubMed ID: 26200278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
    Kang JH; Lee KH; Kim DW; Kim SW; Kim HR; Kim JH; Choi JH; An HJ; Kim JS; Jang JS; Kim BS; Kim HT
    Br J Cancer; 2021 Feb; 124(4):713-720. PubMed ID: 33191408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
    von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
    J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
    Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
    Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
    Allen JW; Moon J; Redman M; Gadgeel SM; Kelly K; Mack PC; Saba HM; Mohamed MK; Jahanzeb M; Gandara DR
    J Clin Oncol; 2014 Aug; 32(23):2463-70. PubMed ID: 25002722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.